Dr Tricia Tan is a Consultant in Diabetes, Endocrinology and Metabolic Medicine at Imperial College London and NHS Trust. She possesses over 10 years’ experience in gut hormone research and physiological studies into the impact of gut hormones on weight and T2DM. She has completed several Phase I trials on the gut hormone analogues, which are being developed for the treatment of obesity. She is the director of the SAS Gut Hormone service, and her clinical research spans a wide gamut from the diagnosis and treatment of neuroendocrine tumours to diagnostic testing in Endocrine disorders.
et al., 2019, Routine clinical use of liraglutide 3 mg for the treatment of obesity: Outcomes in non-surgical and bariatric surgery patients, Diabetes Obesity & Metabolism, Vol:21, ISSN:1462-8902, Pages:1498-1501
et al., 2019, Inadvertent treatment of hypoadrenalism with prednisolone in pemphigus: A case report, Clinical Case Reports, ISSN:2050-0904
et al., 2019, Bile acid mediated changes after bariatric surgery: What can we learn from mouse models?, Gastroenterology, ISSN:0016-5085
et al., 2019, Total small bowel length varies considerably among patients with obesity and diabetes: Is there a role for individualisation of limb lengths in Roux-en-Y gastric bypass?, 10th Annual Scientific Meeting of the British-Obesity-and-Metabolic-Surgery-Society (BOMSS), SPRINGER, Pages:S11-S11, ISSN:0960-8923
et al., 2019, Recent-Onset Type 2 Diabetes Is Defined As < 10 Years Duration, 10th Annual Scientific Meeting of the British-Obesity-and-Metabolic-Surgery-Society (BOMSS), SPRINGER, Pages:S11-S11, ISSN:0960-8923